What Do Banks Risk Working With Trump’s $858 Million Investment Portfolio?
CNBC investigation reveals that JPMorgan Chase, Charles Schwab, UBS, and Stephens Incorporated manage at least four of President Trump's eight investment accounts, which collectively held $858 million in 2025 and generated over 21,000 trades. Financial institutions face significant compliance and reputational risks from managing a sitting president's wealth, while gaining valuable access to presidential influence as compensation.
Summary
CNBC conducted an investigation into President Trump's investment portfolio by analyzing his annual financial disclosures, identifying financial firms connected to at least four of his eight investment accounts. The accounts collectively held at least $858 million in 2025, more than double the previous year's holdings, and executed over 21,000 trades. JPMorgan Chase, Charles Schwab, UBS, and Stephens Incorporated were linked to these accounts through analysis of specific investment funds, deposit programs, and credit arrangements.
One significant finding involves a JPMorgan-linked account that remained active and executed over 300 trades worth up to $5.5 million even after Trump signed an executive order targeting what he described as politically motivated debunking by JPMorgan. Despite Trump later suing JPMorgan for $5 billion, alleging debunking following January 6th, the bank declined to comment on its relationship with Trump's accounts, citing client privacy concerns.
Charles Schwab appears to have the largest relationship with Trump, managing at least one confirmed account and possibly a second. Account number seven, the busiest portfolio, held at least $302 million and generated more than 10,000 transactions in 2025, consistent with investment strategies like direct indexing. The Trump Organization stated that outside money managers control investment decisions while the Trump family oversees the trust, with Trump claiming he doesn't know the specific people managing his investments.
Financial institutions managing Trump's wealth face significant regulatory and reputational pressures. Banks classify Trump as a PEP (politically exposed person), requiring costly oversight including constant monitoring of transfers, checks, and trades. However, these firms accept the risks for tangible benefits: higher fees to compensate for increased risk and, most importantly, valuable access to a sitting president, which experts describe as 'priceless' in business terms.
Key Insights
- CNBC identified JPMorgan Chase, Charles Schwab, UBS, and Stephens Incorporated as managing at least four of Trump's eight investment accounts totaling $858 million in 2025, more than double from the prior year
- A JPMorgan-linked account executed over 300 trades worth up to $5.5 million on August 4th, the day before Trump signed an executive order accusing JPMorgan of political debunking, and continued trading for months afterward
- Charles Schwab appears to have the largest relationship with Trump, managing one confirmed account and a second account that generated 10,000 transactions and held $302 million in 2025
- Trump's revocable trust structure, where he is the sole beneficiary with his son as trustee, provides far less separation than traditional blind trusts used by previous presidents to prevent conflicts of interest
- Financial institutions accept compliance and reputational risks from managing a sitting president's wealth primarily for access to the president, which experts describe as priceless, alongside higher fees to compensate for increased regulatory burden
Topics
Transcript
[0:00] For years, we've known very little about the financial firms connected to President Trump's investments. That is, until now. Cnbc has linked JPMorgan Chase, Charles Schwab, UBS and Stephens Incorporated to at least four of Trump's eight investment accounts. Tracing firms specific investment funds, deposit programs and credit arrangements buried in Trump's annual financial disclosure. Three financial industry experts also independently reviewed the filing and corroborated CNBC's findings. The filing lists eight numbered investment [0:30] accounts that held at least $858 million in 2025, up more than double from a year earlier. Together, they generated more than 21,000 trades last year. While the disclosure does not always define each firm's role or the extent of their relationship, it offers…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Why Fed Chairman Warsh Says 'Inflation Is A Choice'
Fed Chairman Kevin Warsh argues that inflation is fundamentally a choice and responsibility of the Federal Reserve, not an inevitable economic force. The transcript explores how this perspective shapes Fed policy communication and decision-making, while acknowledging the complexity of distinguishing between supply shocks and demand-driven inflation.
How Retail Investors Are Using AI To Make Trades
The transcript explores the evolution of AI in retail investing, moving from AI-powered research tools to autonomous agents that can execute trades on behalf of investors. While some retail investors are building custom AI agents using tools like Claude, current implementations maintain human oversight through approval workflows, with companies cautiously implementing guardrails before AI can act independently on real money.
Why Europe is betting big on drones
Europe is dramatically increasing investment in military drone technology and AI-powered autonomous systems, driven by lessons learned from the Ukraine war. Recent developments include NATO's drone initiative, UK funding pledges, German orders for Ukraine, and major defense tech valuations, signaling that drones and their supporting technologies are now central to modern military strategy.
This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.
Inside the rise and fall of Kohl's
Kohl's, once a beloved department store chain, experienced a dramatic decline from its 2018 peak of $82 per share to under $20, losing 70% of its value over five years. New CEO Michael Bender attributes the decline to the company losing its identity and core customer focus, and is now implementing a turnaround strategy centered on returning to the company's original value-oriented approach.